Neuburgh Advisers’s KALA BIO KALA Stock Holding History

Neuburgh Advisers’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2	Closed	-$59K	–	898
2018 Q2	$59K	Hold	2	–	–	﹤0.01%	835
2018 Q1	$64K	Buy	+2	New	+$75.9K	﹤0.01%	835

Other funds holding KALA

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Neuburgh Advisers's KALA Position: Q3 2018 in Review

Neuburgh Advisers sold out of KALA BIO (KALA) in Q3 2018, closing a stake of 2 shares — an estimated $59K sold.

Neuburgh Advisers first reported a position in KALA in Q1 2018 and held it in 2 quarters. The position peaked at $64K in Q1 2018. 59 funds tracked by Wall St. Rank hold KALA as of Q3 2018.

Neuburgh Advisers reported no remaining KALA BIO position as of Q3 2018 after selling out during the quarter.
Neuburgh Advisers sold 2 KALA BIO shares in Q3 2018, an estimated $59K.
Neuburgh Advisers first reported a position in KALA BIO in Q1 2018 and held it in 2 quarters.
Neuburgh Advisers's KALA BIO position peaked at $64K in Q1 2018.
59 funds tracked by Wall St. Rank held KALA BIO as of Q3 2018.

Based on Neuburgh Advisers's 13F filing for Q3 2018, filed 14 Nov 2018.